Eli Lilly and Company $LLY is UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC's 7th Largest Position

Key Points

• UBS Asset Management Americas LLC reduced its stake in Eli Lilly and Company by 4.3%, now owning approximately $5.6 billion worth of shares.
• Analysts have mixed outlooks on the stock, with UBS cutting its target price from $1,050.00 to $895.00, while Wall Street Zen upgraded the rating from "buy" to "strong-buy."
• Eli Lilly recently reported a 37.6% year-over-year revenue increase, with a net margin of 25.91%, and announced a quarterly dividend of $1.50 per share.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,777,591 shares of the company's stock after selling 307,289 shares during the period. Eli Lilly and Company makes up about 1.4% of UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC's investment portfolio, making the stock its 7th biggest position. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.72% of Eli Lilly and Company worth $5,597,680,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Redwood Investments LLC grew its holdings in Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after purchasing an additional 12 shares during the last quarter. Hobbs Wealth Management LLC grew its stake in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its stake in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Finally, Ascent Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Guggenheim dropped their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Trading Up 0.2%

LLY traded up $1.23 during midday trading on Thursday, hitting $755.85. The company's stock had a trading volume of 2,195,272 shares, compared to its average volume of 4,115,032. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $942.35. The firm has a 50-day moving average price of $742.00 and a two-hundred day moving average price of $779.25. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $715.38 billion, a P/E ratio of 49.40, a PEG ratio of 1.04 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $3.92 EPS. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction dated Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.